Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
NCT07685678
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Neuromyelitis Optica Spectrum Disease (NMOSD)
Ripertamab
Interventions
DRUG:
Ripertamab
Sponsor
Zhongming Qiu